{"disease":{"id":"paraganglioma","name":"Paraganglioma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":4},"drugs":{"marketed":[{"drug_id":"belzutifan","indication_name":"Pheochromocytoma or Paraganglioma (PPGL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Welireg","generic_name":"BELZUTIFAN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"HIF-2α","drug_class":"Hypoxia-inducible Factor Inhibitor [EPC]","quality_score":75,"revenue":"509","mechanism":"Belzutifan inhibits HIF-2α, blocking its interaction with HIF-1β to reduce expression of genes linked to tumor growth."},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic paraganglioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"azedra","indication_name":"Paraganglioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Azedra","company_name":"David Bushnell","drug_phase":"discontinued","molecular_target":"Sodium-dependent noradrenaline transporter","drug_class":"","quality_score":null,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07072143","title":"An International Study on Pediatric Patients With Rare Tumors.","phase":"","overall_status":"RECRUITING","enrollment_count":6250,"lead_sponsor_name":"Azienda Ospedaliera di Padova","has_results":false},{"nct_id":"NCT03160274","title":"Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"The University of Texas Health Science Center at San Antonio","has_results":false},{"nct_id":"NCT03050268","title":"Familial Investigations of Childhood Cancer Predisposition","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT06408402","title":"Impact of Environmental Exposures on Tumor Risk in SDHx-mutation Carriers","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1300,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03344016","title":"Multicenter Pheochromocytoma and Paraganglioma Evaluation","phase":"NA","overall_status":"RECRUITING","enrollment_count":1148,"lead_sponsor_name":"Felix Beuschlein","has_results":false},{"nct_id":"NCT06377033","title":"Using the EHR to Advance Genomic Medicine Across a Diverse Health System","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03583528","title":"DOTATOC PET/CT for Imaging NET Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":800,"lead_sponsor_name":"British Columbia Cancer Agency","has_results":false},{"nct_id":"NCT06523582","title":"Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients","phase":"","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"Universidad Nacional Autonoma de Mexico","has_results":false},{"nct_id":"NCT07412158","title":"Development and Clinical Application of a Novel Imaging Grading System for Pheochromocytoma and Paraganglioma (PPGL)","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT06683846","title":"Ivonescimab in the Treatment of Multiple Advanced Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04788927","title":"Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT06573723","title":"Institutional Registry of Rare Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":380,"lead_sponsor_name":"Hospital Italiano de Buenos Aires","has_results":false},{"nct_id":"NCT04924075","title":"Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":322,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT06503146","title":"18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":320,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05451134","title":"Predictors and Outcomes of Dysglycemia in Pheochromocytoma and Paraganglioma","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"China National Center for Cardiovascular Diseases","has_results":false},{"nct_id":"NCT06870396","title":"National Study of Adrenal Tumours","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":300,"lead_sponsor_name":"Society for Endocrinology","has_results":false},{"nct_id":"NCT02177773","title":"GA-68 DOTA-TOC of Somatostatin Positive Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":300,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT05636618","title":"Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"Perspective Therapeutics","has_results":false},{"nct_id":"NCT04081701","title":"68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":false},{"nct_id":"NCT06444607","title":"Hereditary Pheochromocytoma Assessment of Tumour Immunologies","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT06669481","title":"Correlation Between Preoperative Images of PPGL and Intraoperative Hemodynamics","phase":"","overall_status":"COMPLETED","enrollment_count":159,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT02721732","title":"Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":157,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT07182175","title":"Comparative Study of Perioperative Cardiac Injury in Patients With Functional Adrenal Tumors","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":150,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT04573816","title":"Development of a Tele-monitoring Program for Patients Undergoing Surgery for Pheochromocytoma and / or Paraganglioma","phase":"","overall_status":"UNKNOWN","enrollment_count":139,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03206060","title":"Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":130,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06479811","title":"[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06121271","title":"Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":110,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT07167329","title":"Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"José Claudio Casali da Rocha","has_results":false},{"nct_id":"NCT06440122","title":"The Incidence and Outcomes of Metabolically Active Brown Adipose Tissue (aBAT) in Patients With Pheochromocytoma or Paraganglioma (PPGLs)","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"King's College Hospital NHS Trust","has_results":false},{"nct_id":"NCT04400474","title":"Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"Grupo Espanol de Tumores Neuroendocrinos","has_results":true},{"nct_id":"NCT07282587","title":"Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":false},{"nct_id":"NCT01371201","title":"First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Gustave Roussy, Cancer Campus, Grand Paris","has_results":false},{"nct_id":"NCT04187404","title":"A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":70,"lead_sponsor_name":"Enterome","has_results":true},{"nct_id":"NCT06427798","title":"Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":66,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05858177","title":"The Efficacy and Safety of Temozolomide in Patients With MPPGL","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT04017104","title":"Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging","phase":"","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"British Columbia Cancer Agency","has_results":false},{"nct_id":"NCT05082311","title":"Cardiac and Vascular Changes in Pheochromocytoma and Paraganglioma","phase":"","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","has_results":false},{"nct_id":"NCT04891081","title":"Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"University Medical Centre Ljubljana","has_results":false},{"nct_id":"NCT04394858","title":"Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":46,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07288931","title":"Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT05942482","title":"Head and Neck Paragangliomas: A 16-year Experience of a University Hospital in Turkey","phase":"","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Pamukkale University","has_results":false},{"nct_id":"NCT03176693","title":"Preoperative Alpha Blockade for Pheochromocytoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"University of California, Los Angeles","has_results":true},{"nct_id":"NCT05948137","title":"F-18 FDOPA PET/CT Versus I-123 MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma","phase":"","overall_status":"TERMINATED","enrollment_count":32,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT07195500","title":"Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Nanjing First Hospital, Nanjing Medical University","has_results":false},{"nct_id":"NCT02186678","title":"Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false},{"nct_id":"NCT05636540","title":"In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Heather Wachtel","has_results":false},{"nct_id":"NCT04860700","title":"The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT05702944","title":"The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT02592356","title":"Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}